Dr. Baselga Discusses Upcoming BOLERO-3 Data

Jose Baselga, MD, PhD
Published: Thursday, Apr 18, 2013

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses everolimus and the upcoming data from the BOLERO-3 trial in breast cancer.

In addition to the data regarding everolimus in ER-positive tumor, there is also evidence demonstrating that everolimus can enhance the effect of trastuzumab in patients with HER2-positive disease.

Data from the BOLERO-3 trial will be released soon, Baselga says. He is hopeful that the data will show benefit and provide another option for patients with HER2-positive disease.

SELECTED
LANGUAGE
José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses everolimus and the upcoming data from the BOLERO-3 trial in breast cancer.

In addition to the data regarding everolimus in ER-positive tumor, there is also evidence demonstrating that everolimus can enhance the effect of trastuzumab in patients with HER2-positive disease.

Data from the BOLERO-3 trial will be released soon, Baselga says. He is hopeful that the data will show benefit and provide another option for patients with HER2-positive disease.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x